• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company?s drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution?s Chemetics platform chemistry technology. The company was founded in 1995 and is headquartered in The Woodlands, Texas.

NO
     
LXRX (Lexicon Pharmaceuticals Inc)
Last Trade 2.9 Date 2/15/2020
Change % -3.34 % Price Change -0.10
Open 3.0 52 Week High 8.39
High 3.0576 52 Week Low 1.125
Low 2.85 Type stock
Volume 862408 Average Volume 1289704
Prev Close 3.0 Stock Exchange NASDAQ
Bid 2.89 Ask 2.91
Bid Size 2 Ask Size 1
1st Yr Estimated EPS Growth -2.2087 2nd Yr Estimated EPS Growth -0.359
2 Years Forward Earning Yield -0.431 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA -2.2744
Book Value per Share 1.5499 Book Value Yield 0.5345
Buy Back Yield 0.0025 CAPE Ratio
Cash Return 0.4905 Cash Flow per Share 0.9738
Cash Flow Yield 0.3358 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield 0.4931 EV/EBIT 1.4343
EV/EBITDA 1.4059 EV / Free Cash Flow 2.3166
EV / Forward EBIT EV / Forward EBITDA -1.3386
EV / Forward Revenue 5.5872 EV / Pre Tax Income 1.6218
EV / Revenue 0.7778 EV / Total Asset 0.5781
Expected Dividend Growth Rate Free Cash Flow per Share 0.9729
Free Caash Flow Ratio 2.980863 Free Cash Flow Yield 0.3355
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.6724 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio 1.79753 Payout Ratio 0.0
PB Ratio 1.871076 PB Ratio 10 Year Growth -0.008521
PB Ratio 3 Year Growth 16.144421 Cash Ratio 3 Year Average 429.1627
Price to Cash Flow Ratio 2.977991 PEG Payback
PEG Ratio PE Ratio 2.027972
PE Ratio 10 Year Average 2.691587 PE Ratio 10 Year Growth
PE Ratio 10 Year High 3.601399 PE Ratio 10 Year Low 2.027972
PE Ratio 1 Year Avg 2.691587 PE Ratio 1 Year High 3.601399
PE Ratio 1 Year Low 2.027972 PE Ratio 3 Year Avg 2.691587
PE Ratio 5 Year Avg 2.691587 PE Ratio 5 Year High 3.601399
PE Ratio 5 Year Low 2.027972 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 5.117023 Price Change 1 Month 0.938511
Price to Cash Ratio 1.040109 Price / EBITDA 1.808965
Price to Sales Ratio 1.000874 Price to Sales Ratio 10 Year Growth -0.277521
Price to Sales Ratio 3 Year Avg 11.38015 Price to Sales Ratio 5 Year Avg 2.691587
Sale per Share 2.8975 Sales Yield 0.9991
Sustainable Growth Rate 2.4313 Tangible Book Value per Share 0.9411
Tangible Book Value per Share 3 year Avg -0.1365 Tangible Book Value per Share 5 year Avg 0.2786
Total Asset per Share 4.1835 Total Yield 0.0025
Working Capital per Share 2.9996 Working Capital per Share 3 Year Avg 1.6778
Working Capital per Share 5 Year Avg 1.9029 Beta 1.640104